Genome-wide Methylation Profiling Identifies Novel Methylated Genes in Neuroblastoma Tumors

Overview

Journal Epigenetics

Specialty Genetics

Date 2016 Jan 21

PMID 26786290

Citations 46

Authors

Maja Olsson

Stephan Beck

Per Kogner

Tommy Martinsson

Helena Caren

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a very heterogeneous tumor of childhood. The clinical spectra range from very aggressive metastatic disease to spontaneous regression, even without therapy. Aberrant DNA methylation pattern is a common feature of most cancers. For neuroblastoma, it has been demonstrated both for single genes as well as genome-wide, where a so-called methylator phenotype has been described. Here, we present a study using Illumina 450K methylation arrays on 60 neuroblastoma tumors. We show that aggressive tumors, characterized by International Neuroblastoma Risk Group (INRG) as stage M, are hypermethylated compared to low-grade tumors. On the contrary, INRG stage L tumors display more non-CpG methylation. The genes with the highest number of hypermethylated CpG sites in INRG M tumors are TERT, PCDHGA4, DLX5, and DLX6-AS1. Gene ontology analysis showed a representation of neuronal tumor relevant gene functions among the differentially methylated genes. For validation, we used a set of independent tumors previously analyzed with the Illumina 27K methylation arrays, which confirmed the differentially methylated sites. Top candidate genes with aberrant methylation were analyzed for altered gene expression through the R2 platform ( http://r2.amc.nl), and for correlations between methylation and gene expression in a public dataset. Altered expression in nonsurvivors was found for the genes B3GALT4 and KIAA1949, CLIC5, DLX6-AS, TERT, and PIRT, and strongest correlations were found for TRIM36, KIAA0513, and PIRT. Our data indicate that methylation profiling can be used for patient stratification and informs on epigenetically deregulated genes with the potential of increasing our knowledge about the underlying mechanisms of tumor development.

Citing Articles

Prediction of Composite Clinical Outcomes for Childhood Neuroblastoma Using Multi-Omics Data and Machine Learning.

Wang P, Zhang J Int J Mol Sci. 2025; 26(1.

PMID: 39795994 PMC: 11720239. DOI: 10.3390/ijms26010136.

Altered methylation of imprinted genes in neuroblastoma: implications for prognostic refinement.

Suman M, Lofgren M, Fransson S, Yousuf J, Svensson J, Djos A J Transl Med. 2024; 22(1):808.

PMID: 39217334 PMC: 11366169. DOI: 10.1186/s12967-024-05634-5.

Targeting DNA Methylation Machinery in Pediatric Solid Tumors.

Cristalli C, Scotlandi K Cells. 2024; 13(14.

PMID: 39056791 PMC: 11275080. DOI: 10.3390/cells13141209.

Telomere Maintenance Mechanisms in a Cohort of High-Risk Neuroblastoma Tumors and Its Relation to Genomic Variants in the and Genes.

Djos A, Thombare K, Vaid R, Gaarder J, Umapathy G, Reinsbach S Cancers (Basel). 2023; 15(24).

PMID: 38136279 PMC: 10741428. DOI: 10.3390/cancers15245732.

Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA.

Trinidad E, Vidal E, Coronado E, Esteve-Codina A, Castel V, Canete A Brief Bioinform. 2023; 24(1).

PMID: 36611239 PMC: 9851319. DOI: 10.1093/bib/bbac575.

References

Kent W, Sugnet C, Furey T, Roskin K, Pringle T, Zahler A . The human genome browser at UCSC. Genome Res. 2002; 12(6):996-1006. PMC: 186604. DOI: 10.1101/gr.229102. View

Tocchini C, Ciosk R . TRIM-NHL proteins in development and disease. Semin Cell Dev Biol. 2015; 47-48:52-9. DOI: 10.1016/j.semcdb.2015.10.017. View

Alaminos M, Davalos V, Cheung N, Gerald W, Esteller M . Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst. 2004; 96(16):1208-19. DOI: 10.1093/jnci/djh224. View

Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y . CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 2005; 65(3):828-34. View

Caren H, Fransson S, Ejeskar K, Kogner P, Martinsson T . Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer. 2007; 97(10):1416-24. PMC: 2360241. DOI: 10.1038/sj.bjc.6604032. View

Abe M, Watanabe N, McDonell N, Takato T, Ohira M, Nakagawara A . Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology. 2008; 74(1-2):50-60. DOI: 10.1159/000139124. View

Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg R, Abrahamsson J . High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics. 2008; 9:353. PMC: 2527340. DOI: 10.1186/1471-2164-9-353. View

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, De Pontual L, Combaret V . Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455(7215):967-70. DOI: 10.1038/nature07398. View

10.

Chen Y, Takita J, Choi Y, Kato M, Ohira M, Sanada M . Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008; 455(7215):971-4. DOI: 10.1038/nature07399. View

11.

George R, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J . Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008; 455(7215):975-8. PMC: 2587486. DOI: 10.1038/nature07397. View

12.

Caren H, Abel F, Kogner P, Martinsson T . High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008; 416(2):153-9. DOI: 10.1042/bj20081834. View

13.

Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N . Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett. 2008; 273(2):336-46. DOI: 10.1016/j.canlet.2008.08.019. View

14.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

15.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

16.

Miyajima N, Maruyama S, Nonomura K, Hatakeyama S . TRIM36 interacts with the kinetochore protein CENP-H and delays cell cycle progression. Biochem Biophys Res Commun. 2009; 381(3):383-7. DOI: 10.1016/j.bbrc.2009.02.059. View

17.

El Andaloussi-Lilja J, Lundqvist J, Forsby A . TRPV1 expression and activity during retinoic acid-induced neuronal differentiation. Neurochem Int. 2009; 55(8):768-74. DOI: 10.1016/j.neuint.2009.07.011. View

18.

Caren H, Kryh H, Nethander M, Sjoberg R, Trager C, Nilsson S . High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010; 107(9):4323-8. PMC: 2840092. DOI: 10.1073/pnas.0910684107. View

19.

Yang Q, Tian Y, Ostler K, Chlenski A, Guerrero L, Salwen H . Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer. 2010; 10:286. PMC: 2897803. DOI: 10.1186/1471-2407-10-286. View

20.

Caren H, Djos A, Nethander M, Sjoberg R, Kogner P, Enstrom C . Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer. 2011; 11:66. PMC: 3045360. DOI: 10.1186/1471-2407-11-66. View